CPIX लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (18 May 2024 @ 01:30):

Stats
आज की मात्रा	4 121.00
औसत मात्रा	10 901.00
बाजार मूल्य	21.43M
EPS	$0 ( 2024-05-14 )
अगली कमाई की तारीख	( $0 ) 2024-08-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.43
ATR14	$0.0170 (1.08%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-25	Krogulski Kenneth	Buy	5 000	Common Stock
2024-03-25	Jones James	Buy	1 000	Common Stock
2024-03-25	Galante Joseph C	Buy	1 000	Common Stock
2024-03-25	Young Caroline	Buy	1 000	Common Stock
2024-03-25	Brown Martin S Jr	Buy	1 000	Common Stock

INSIDER POWER
64.38
Last 100 transactions
Buy: 135 322 \| Sell: 29 102

Cumberland सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध
DMRC	0.907
GTEC	0.894
LUNA	0.893
NEPH	0.893
AZ	0.891
DLHC	0.888
TELA	0.888
ZS	0.886
TACT	0.883
MTEM	0.881

10 सबसे अधिक नकारात्मक सहसंबंध
IGLD	-0.878
ROOT	-0.873
STAA	-0.868
KNTK	-0.866
VTVT	-0.864
KALU	-0.863
VITL	-0.862
PPTA	-0.861
TIGO	-0.861
BNR	-0.86

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Cumberland वित्तीय

Annual	2023
राजस्व:	$39.55M
सकल लाभ:	$28.55M (72.18 %)
EPS:	$-0.440

FY	2023
राजस्व:	$39.55M
सकल लाभ:	$28.55M (72.18 %)
EPS:	$-0.440

FY	2022
राजस्व:	$42.01M
सकल लाभ:	$32.89M (78.29 %)
EPS:	$-0.390

FY	2021
राजस्व:	$35.99M
सकल लाभ:	$27.17M (75.51 %)
EPS:	$-0.240

Financial Reports:

No articles found.

Cumberland Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Cumberland

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.